De Novo RB1 Germline Variant in Retinoblastoma with Two Subsequent Independent Neoplasms: Case Report and Literature Review

Abstract

Variants in the RB1 gene are associated with retinoblastoma (RB) development, and their presence in germline cells considerably increases the risk of subsequent malignant neoplasms (SMNs) in RB survivors. We report a female patient with bilateral RB who developed two SMNs in less than ten years, with a de novo pathogenic nonsense variant in RB1 [NM_000321.3:c.306T>A, p.(Cys102*)] in heterozygosity. The updated literature review of similar cases of SMN in patients with a previous diagnosis of RB reveals a wide range in both the type of subsequent malignancy and the age at which these SMNs develop. In addition, we identified only three cases with two SMNs following RB diagnosis, with at least one of these being an EWS. This case broadens the clinical and genetic landscape of RB, demonstrates the importance of a multidisciplinary approach in these patients, and highlights genetic diagnosis as a mandatory feature for management.

1. Introduction

Retinoblastoma (RB) is a rare childhood cancer. However, it accounts for most ocular neoplasms that develop in pediatric patients, with an overall incidence of 1 in 15–20,000 live births. RB can be divided into two major groups: hereditary and non-hereditary. The hereditary group accounts for about 30% of all cases, with a mean age at diagnosis of 12.3 months, usually with bilateral disease, and is characterized by germline cytogenomic alterations in the RB1 gene [1]. Being a tumor-suppressor gene, RB1 germline inactivation in patients previously diagnosed with hereditary RB has up to 20 times higher susceptibility to develop subsequent malignant neoplasms (standardized incidence ratio (SIR) = 20.4 (confidence interval (CI) 15.6–26.1)) (SMN) [2,3,4,5,6], and the risk of presenting a third neoplasm after a second is up to 8 times higher compared to the general population risk (SIR = 8.5 (CI 3.7–16.7)) [7,8]. In clinical practice, standard RB treatment with radiotherapy and chemotherapy (especially when using alkylating agents) has been associated with an increased risk of developing SMNs [9]. A wide variety of SMNs have been reported in RB survivors, such as leukemias and lymphomas (4%), melanoma (8%), carcinomas (13%), central nervous system tumors (3%) and sarcomas (60%), the latter being the most common among patients with RB. Ewing sarcomas (EWSs) accounts for less than 5% of all SMNs in patients with a previous diagnosis of RB [9,10,11]. Herein, we aim to present a patient with RB who presented two SMNs associated with a germline pathogenic variant in RB1 detected by Next Generation Sequencing (NGS).

2. Case Presentation

The proband, a female infant, presented with bilateral leukocoria at three months of age and was referred to the pediatric ophthalmology service, where bilateral RB without optic nerve infiltration was diagnosed (Figure 1A). The tumor in the left eye was classified as group E according to the International Classification of Retinoblastoma (ICRB) and was enucleated; the tumor in the right eye was classified as group B and received transpupillary thermotherapy (TTT). No evidence of optic nerve infiltration was found as assessed by magnetic resonance imaging (MRI) or infiltration at bone marrow by biopsy. Adjuvant chemotherapy was administered in six cycles of VCE (vincristine, carboplatin, etoposide) and resulted in complete remission. The patient was monitored with annual follow-up appointments with hemato-oncology. We conducted a comprehensive evaluation in the genetics department, with no hereditary history of cancer or relevant pathological background, and initiated a cytogenomic approach in search of germline RB1 gene variants.

The first SMN was diagnosed at five years of age when she presented with pain and increased volume in the left forearm due to a cubital tumor (Figure 1B). A biopsy was performed, and the histopathologic result showed small round blue cell neoplasia with bone infiltration compatible with EWSs. She was treated with a supracondylar amputation of the left forearm, followed by adjuvant chemotherapy, with a complete post-treatment response observed and no evidence of residual neoplasia.

The second SMN presented at the age of 9 years, with the patient reporting pain and an increase in volume in the right maxillary region. An MRI showed a lobulated tumor in the right maxilla and maxillary process of the zygomatic bone with extension to the ipsilateral maxillary sinus space (Figure 1C,D). Biopsy results indicated a sarcoma with CD99-positive immunohistochemistry. Due to the aggressive behavior of this neoplasm and the compromise of facial structures, palliative care was offered with metronomic chemotherapy and pain management. The patient evolved torpidly, and three months after diagnosis, she died due to complications of the third neoplasm.

Karyotype analysis results were 46,XX (Figure 2A); fluorescence in situ hybridization (FISH) and Multiplex Ligation-dependent Probe Amplification (MLPA) analysis revealed two copies of the RB1 gene (Figure 2B,C). Through NGS analysis, a heterozygous NM_000321.3 (RB1):c.306T>A, (p.Cys102*) variant was identified in our patient (Figure 3). The RB1 gene of both parents was normal, although paternal identity was assumed but not confirmed. FISH analysis of tumor tissue from the second SMN revealed the EWSR1/ERG fusion gene (Figure 2D).

3. Discussion

The patient presented in this case report with early-onset bilateral RB developed two independent SMNs due to a germline de novo pathogenic variant in RB1. We identified a NM_000321.3:c.306T>A, p.(Cys102*) nonsense RB1 pathogenic variant, which was classified as pathogenic according to American College of Medical Genetics (ACMG) variant classification guidelines [12], based on: (a) its effect at the protein level since it generates a null allele in a gene whose loss of function is a known mechanism of disease, (b) its low frequency based on gnomeAD population databases (<0.05%) and (c) de novo data, regarding a patient with consistent phenotype (d) reputable source data, reputable source recently reports variant as pathogenic; RB1 c.306T>A, nonsense variant classified as Pathogenic [13].

Exposure to radiotherapy and the administration of specific chemotherapeutic agents elevate the risk of SMN, especially in patients with hereditary RB [14]. A threefold increase in SMN occurrence in patients with hereditary RB treated with radiotherapy compared to patients with non-irradiated hereditary RB was found in a U.S. [3] and a Dutch cohort [4]. Exposure to radiotherapy also affects the onset of SMNs, as patients with hereditary RB treated with radiotherapy present early-onset SMNs more frequently than patients with non-irradiated hereditary RB [11]. There appears to be a dose-response relationship between high doses of radiotherapy and a higher risk of developing osteosarcoma and soft tissue sarcoma [15]. Treatment with anthracyclines and alkylating agents is another known risk factor for the development of SMNs in cancer survivors [16]. In a U.S. cohort of patients previously diagnosed with RB, systemic chemotherapy was identified as a risk factor for SMNs [3]. An excess in leukemia incidence in RB survivors treated with eye-preserving chemotherapy was identified in Argentine [17] and German [18] cohorts. Chemotherapy regimens that include alkylating agents and topoisomerase inhibitors are the most used in RB, and their possible involvement with the presence of subsequent tumors is known, especially when combined with radiotherapy [19]. However, the impact of chemotherapy without radiotherapy in patients with hereditary RB is poorly described [18].

Environmental factors play a fundamental role in developing multiple types of cancer. Generally speaking, these factors include air pollution, exposure to chemicals and radiation [20]. In the particular case of retinoblastoma, because of its embryonic origin, the environmental risk factors will be those to which the parents were exposed before or during pregnancy. Smoking, exposure to pesticides, toxic air and residence near industrial areas have been linked to the development of retinoblastoma [20,21,22]. For Ewing’s sarcoma, the environmental risk factors will also include parental occupational exposures, including but not limited to exposure to herbicides, insecticides and fertilizers [23]. The patient’s parents deny exposure to any known environmental risk factors from occupational exposures or tobacco use before or during pregnancy, and the patient herself was not exposed to any of these environmental risk factors at a young age.

The occurrence of SMNs in RB patients is also closely linked to germline variants in the RB1 tumor-suppressor gene [9]. Although extrinsic factors such as radiotherapy or chemotherapy with alkylating factors have been associated, germline variants in RB1 increase the risk of SMNs, even in patients who were only enucleated and were not exposed to radiation or chemotherapy [24,25,26,27]. Our patient did not undergo radiotherapy, neither external beam nor brachytherapy, the cumulative dose of carboplatin as an alkylating agent in VCE chemotherapy regimen did not exceed the recommended, and parents deny occupational, lifestyle or environmental risk exposures. Given the lack of evidence of known extrinsic factors involved in the development of the three malignancies and the presence of a germline pathogenic variant in a gene (RB1) whose loss of function is a known mechanism of tumorigenesis, we have convincing elements to ensure that the presence of intrinsic factors was the main responsible for the development of the three neoplasms.

Cell cycle deregulation is a mechanism involved in the appearance and development of most malignant tumors [28]. In RB, this deregulation arises in most cases with the biallelic loss of function of the tumor-suppressor gene RB1, whose product acts as a negative regulator of the cell cycle, which in its hypophosphorylated state binds to the transcription factor E2F inhibiting the transcription of genes that promote cell cycle progression. Moreover, in the presence of mitogenic signals, RB protein is hyperphosphorylated by cyclin/CDK complexes, causing the protein to dissociate from E2F, allowing progression through G1 into the S phase of the cell cycle [29]. In EWSs, the main one responsible for cell cycle dysregulation is the chimeric oncogene product resulting from the fusion of the EWSR1 gene and ETS family genes. The oncoprotein promotes cyclin D1 overexpression and modulates cyclin E levels, leading to RB protein hyperphosphorylation without external mitogenic signals [29,30]. Inactivation of the RB protein is caused by variants in the RB1 gene, although it can occur, and is an infrequent phenomenon in EWSs. We provide evidence of a nonsense germline pathogenic variant in the RB1 gene and the presence of the EWRS1/ERG fusion gene in EWS tumor tissue in our patient. The germline variant in RB1 alone was likely sufficient for the cell cycle deregulation that triggered tumorigenesis in all three neoplasms. However, in the case of an EWS, its early development and rapid progression may be due to the additive effect of the loss of function of RB1 and the presence of the EWSR1/ERG fusion gene.

To further support our hypothesis that the germline variant in the RB1 gene as an intrinsic risk factor is sufficient for the development of RB and multiple SMNs even in the absence of extrinsic risk factors, we performed an extensive literature search of the Pubmed database for articles published through August 2024 to identify case reports of patients with RB who developed at least one SMN and EWS being at least one of these SMNs (Table 1). We observed a wide range of subsequent neoplasms in age of onset, from 4 to 20 (mean = 10.7 (standard deviation (SD) 5.17)) years for the first and 9 to 35.8 (mean = 19.8 SD 12.7) years for the second SMN. Most of these patients were treated with radiotherapy, and no germline pathogenic variant in RB1 was evidenced. Bilateral RB was present in 12 out of the 18 cases [8,31,32,33,34,35,36,37], and no evidence of germinal cytogenetic alterations was reported. However, such alterations probably conferred a higher risk of SMNs regardless of treatment in these patients. The probability of undiagnosed germline cytogenetic alterations is less in the six patients with unilateral RB [33,37,38,39,40]. Although it is not ruled out, it is likely that in these cases, the choice of treatment and environmental factors have had a greater weight in the development of SMNs. Furthermore, the four patients who developed a second SMN had a previous diagnosis of bilateral RB [8,34,36]; this reinforces the idea of germline alterations in RB1 as an intrinsic risk factor of high relevance in the development of SMNs in these patients. Radiotherapy is known to increase the risk of SMNs [35]; 61.11% of the patients in our review were exposed to some radiotherapy, which is a frequent treatment that increases this risk for patients with RB for SMNs considering the intrinsic risk of SMNs with patients with hereditary RB and the increased risk with this de novo mutation in the RB1 gene presented in our case.

4. Conclusions

In summary, this case expands the clinical and genetic landscape of RB. To the best of our knowledge, it represents the first report of RB with multiple SMNs for which there is evidence of a germline variant in the RB1 gene. The RB1 variant identified in the patient is likely a significant driver of tumorigenesis, contributing to the development of both RB and the two SMNs, even without high doses of alkylating agents and radiotherapy. The effect of the variant in the RB1 gene has been reported as pathogenic in only one patient, diagnosed at one month of age with bilateral retinoblastoma, who, like our patient, had a de novo mode of inheritance; it is unknown whether a second neoplasia was subsequently found or the patient’s clinical picture. However, additional genetic and environmental factors may also play a role. Genetic testing should be considered for identifying germline variants in patients with RB, especially in bilateral cases. Although identifying these variants is sometimes challenging, the presence of a pathogenic germline variant in the RB1 gene will, in all cases, signify an extremely high risk for the development of SMNs in these patients and will become high-impact evidence for clinical management and long-term follow-up.

Author Contributions

Conceptualization, L.B.-M., F.d.J.B.-R. and G.G.-P.; methodology, J.d.J.P.-B., V.U.R.-M., M.T.A.G.-R., S.A.B.-J. and J.A.R.-C.; formal analysis, L.B.-M., V.U.R.-M. and S.A.B.-J.; investigation, J.d.J.P.-B., V.U.R.-M., M.T.A.G.-R., S.A.B.-J., J.A.R.-C. and X.A.R.-U.; resources, L.B.-M. and A.C.-R.; writing—original draft preparation, J.d.J.P.-B., V.U.R.-M., M.T.A.G.-R. and I.C.-Q.; writing—review and editing, J.d.J.P.-B., V.U.R.-M. and J.A.R.-C.; supervision, A.C.-R. and J.R.C.-R. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

The study was conducted following the Declaration of Helsinki and approved by the Ethics Committee of Dr. Juan I. Menchaca Civil Hospital of Guadalajara (protocol code: 0658/23 HCJIM/2023, approval: 18 January 2024).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

Data is contained within the article.

Acknowledgments

The authors gratefully thank the parents for consenting to the publication of this report. The authors received a scholarship from Consejo Nacional de Humanidades, Ciencia y Tecnología, Mexico.

Conflicts of Interest

The authors declare no conflicts of interest.

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Figures and Table

Figure 1. (A) Multifocal RB in the right eye with calcium content in its interior. (B) MRI of the left forearm showing a hyperintense lesion in the cubitus with disruption of bone cortex. (C) Head MRI at time of diagnosis showing a giant lobulated tumor in the right maxilla with extension to the ipsilateral maxillary sinus space. (D) Head MRI three months after diagnosis showing a giant lobulated tumor in the right maxilla with extension to the ipsilateral maxillary sinus space.

Figure 2. (A) Karyotype of the patient with G-band staining showing a 46,XX[20] result. (B) FISH of interphase chromosomes on peripheral blood cells showing a nuc ish (RB1,LAMP1)x2 [200] result. (C) MLPA copy number variant analysis of RB1 gene showing an rsa 13q14.2(RB1)x2 result. (D) FISH of interphase chromosomes of third neoplasm (Ewing sarcoma) showing fusion between EWSR1::ERG genes (yellow arrows).

Figure 3. NGS analysis and Sanger sequencing trio analysis of the identified variant in our patient. (A) NGS analysis of RB1 gene in the patient. (B) Depth of reads and variant allelic balance in the patient’s RB1 gene. (C) Sanger sequencing of the patient showing a transversion (T>A) in nucleotide 306 of the coding DNA. (D) Electropherogram of the father. (E) Electropherogram of the mother.

Table 1

Case reports of patients with RB who developed at least one SMN and EWS.

Sex	Age at DiagnosisRB	Laterality	Familial Case	Therapy	Age at DiagnosisFirst SMN	Type	Location	Age at DiagnosisSecond SMN	Type	Germline Variant	Reference
F	3 m	B	−	En, QT	5 y	Sarcoma	Left ulna	9 y	EWS	c.306T>A (p.Cys102*)	Present case
F	5 m	B		RT	7 y	EWS	Femur	-	-	NI	Kitchin (1974) Case 1 [31]
F	5 m	B		RT	14 y	EWS	Femur	-	-	NI	Kitchin (1974) Case 1 [31]
F	18 m	B	−	En, BT	9 y	EWS	Right ulna	-	-	NI	Schifter (1983) [32]
F	8 m	B	+	QT, RT	12.5 y	EWS	Right ankle	-	-	NI	Helton (1993) Case 1 [33]
M	2 y	U	−	En	20 y	EWS	Left ilium	-	-	NI	Helton (1993) Case 2 [33]
F	1 y	U	−	En	11 y	EWS	Right ankle	-	-	NI	Helton (1993) Case 3 [33]
F	18 m	B	+	En, RT	4 y	EWS	Right distal femur	9 y	Osteosarcoma	NI	Kay (1996) [34]
F	8 m	U	NS	QT, RT	12 y	EWS	Scapula	-	-	NI	Okeda (1997) [38]
F	12 m	B	−	En, RT, QT	20 y	EWS	Left fibula	29 y	Osteosarcoma	NI	Ceha (1998) [35]
M	9 m	B	NS	QT	15 y	EWS	Metatarsal				Mohney (1998) Case 10 [36]
NS	11 m	B	+	En, RT, QT	10 y	Osteosarcoma	Zygomatic bone	-	-	NI	Aerts (2004)Case 2 [37]
NS	22 m	B	−	En, RT, QT	7 y	Osteosarcoma	Left humerus	-	-	NI	Aerts (2004)Case 10 [37]
NS	30 m	U	+	En, RT	11 y	Malignant mesenchymal tumor	Left maxillary sinus	-	-	NI	Aerts (2004)Case 24 [37]
M	9 m	U	NS	En, QT	5 y	EWS	Right fibula	-	-	NI	Mittal (2008) [39]
F	NS	B	NS	RT	18.4 y	EWS	Knee	35.8 y	Osteosarcoma	NI	Marees (2010)Case 7 [8]
F	NS	B	NS	RT	8 y	Soft tissue	Zygoma	16.3 y	Orbit	NI	Marees (2010)Case 11 [8]
M	36 m	U	NS	En, QT	5 y	EWS	Right distal humerus	-	-	NI	Tahasildar (2011) [40]

F = female; M = male; NS = not specified; B = bilateral; U = unilateral; En = enucleation; QT = chemotherapy; RT = radiotherapy; BT = brachytherapy; NI = not investigated; m = months; y = years.

References

1. Fabian, I.D.; Abdallah, E.; Abdullahi, S.U.; Abdulqader, R.A.; Adamou Boubacar, S.; Ademola-Popoola, D.S.; Adio, A.; Afshar, A.R.; Aggarwal, P.; Aghaji, A.E. et al. Global Retinoblastoma Presentation and Analysis by National Income Level. JAMA Oncol.; 2020; 6, pp. 685-695. [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32105305]

2. Fletcher, O.; Easton, D.; Anderson, K.; Gilham, C.; Jay, M.; Peto, J. Lifetime risks of common cancers among retinoblastoma survivors. J. Natl. Cancer Inst.; 2004; 96, pp. 357-363. [DOI: https://dx.doi.org/10.1093/jnci/djh058] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14996857]

3. Kleinerman, R.A.; Tucker, M.A.; Tarone, R.E.; Abramson, D.H.; Seddon, J.M.; Stovall, M.; Li, F.P.; Fraumeni, J.F. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: An extended follow-up. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.; 2005; 23, pp. 2272-2279. [DOI: https://dx.doi.org/10.1200/JCO.2005.05.054] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15800318]

4. Marees, T.; Moll, A.C.; Imhof, S.M.; de Boer, M.R.; Ringens, P.J.; van Leeuwen, F.E. Risk of second malignancies in survivors of retinoblastoma: More than 40 years of follow-up. J. Natl. Cancer Inst.; 2008; 100, pp. 1771-1779. [DOI: https://dx.doi.org/10.1093/jnci/djn394]

5. Gregersen, P.A.; Olsen, M.H.; Urbak, S.F.; Funding, M.; Dalton, S.O.; Overgaard, J.; Alsner, J. Incidence and Mortality of Second Primary Cancers in Danish Patients With Retinoblastoma, 1943–2013. JAMA Netw. Open; 2020; 3, e2022126. [DOI: https://dx.doi.org/10.1001/jamanetworkopen.2020.22126]

6. MacCarthy, A.; Bayne, A.M.; Brownbill, P.A.; Bunch, K.J.; Diggens, N.L.; Draper, G.J.; Hawkins, M.M.; Jenkinson, H.C.; E Kingston, J.; A Stiller, C. et al. Second and subsequent tumours among 1927 retinoblastoma patients diagnosed in Britain 1951–2004. Br. J. Cancer; 2013; 108, pp. 2455-2463. [DOI: https://dx.doi.org/10.1038/bjc.2013.228]

7. Abramson, D.H.; Melson, M.R.; Dunkel, I.J.; Frank, C.M. Third (fourth and fifth) nonocular tumors in survivors of retinoblastoma. Ophthalmology; 2001; 108, pp. 1868-1876. [DOI: https://dx.doi.org/10.1016/S0161-6420(01)00713-8] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11581064]

8. Marees, T.; van Leeuwen, F.E.; Schaapveld, M.; Imhof, S.M.; de Boer, M.R.; Kors, W.A.; Ringens, P.J.; Moll, A.C. Risk of third malignancies and death after a second malignancy in retinoblastoma survivors. Eur. J. Cancer; 2010; 46, pp. 2052-2058. [DOI: https://dx.doi.org/10.1016/j.ejca.2010.03.029]

9. Fabius, A.W.M.; van Hoefen Wijsard, M.; van Leeuwen, F.E.; Moll, A.C. Subsequent Malignant Neoplasms in Retinoblastoma Survivors. Cancers; 2021; 13, 1200. [DOI: https://dx.doi.org/10.3390/cancers13061200]

10. Abramson, D.H.; Ellsworth, R.M.; Kitchin, F.D.; Tung, G. Second nonocular tumors in retinoblastoma survivors. Are they radiation-induced?. Ophthalmology; 1984; 91, pp. 1351-1355. [DOI: https://dx.doi.org/10.1016/S0161-6420(84)34127-6]

11. Woo, K.I.; Harbour, J.W. Review of 676 second primary tumors in patients with retinoblastoma: Association between age at onset and tumor type. Arch. Ophthalmol.; 2010; 128, pp. 865-870. [DOI: https://dx.doi.org/10.1001/archophthalmol.2010.126] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20625047]

12. Harrison, S.M.; Biesecker, L.G.; Rehm, H.L. Overview of Specifications to the ACMG/AMP Variant Interpretation Guidelines. Curr. Protoc. Hum. Genet.; 2019; 103, e93. [DOI: https://dx.doi.org/10.1002/cphg.93] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31479589]

13. Hoang, C.Q.; Duong, H.Q.; Nguyen, N.T.; Nguyen, S.A.H.; Nguyen, C.; Nguyen, B.D.; Phung, L.T.; Nguyen, D.T.; Pham, C.T.M.; Le Doan, T. et al. Clinical evaluation of RB1 genetic testing reveals novel mutations in Vietnamese patients with retinoblastoma. Mol. Clin. Oncol.; 2021; 15, 182. [DOI: https://dx.doi.org/10.3892/mco.2021.2344] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34277001]

14. Sun, J.; Gu, X.; Wang, L. Incidence of second primary cancers in patients with retinoblastoma: A systematic review and meta-analysis. Front. Oncol.; 2024; 14, 1372548.

15. Wong, F.L.; Boice John, D.J.; Abramson, D.H.; Tarone, R.E.; Kleinerman, R.A.; Stovall, M.; Goldman, M.B.; Seddon, J.M.; Tarbell, N.; Fraumeni, J.F. et al. Cancer Incidence After Retinoblastoma: Radiation Dose and Sarcoma Risk. JAMA; 1997; 278, pp. 1262-1267. [DOI: https://dx.doi.org/10.1001/jama.1997.03550150066037]

16. Henderson, T.O.; Moskowitz, C.S.; Chou, J.F.; Bradbury, A.R.; Neglia, J.P.; Dang, C.T.; Onel, K.; Friedman, D.N.; Bhatia, S.; Strong, L.C. et al. Breast Cancer Risk in Childhood Cancer Survivors Without a History of Chest Radiotherapy: A Report From the Childhood Cancer Survivor Study. J. Clin. Oncol.; 2016; 34, pp. 910-918. [DOI: https://dx.doi.org/10.1200/JCO.2015.62.3314]

17. Chantada, G.L.; Fandiño, A.C.; Schvartzman, E.; Raslawski, E.; Schaiquevich, P.; Manzitti, J. Impact of chemoreduction for conservative therapy for retinoblastoma in Argentina. Pediatr. Blood Cancer; 2014; 61, pp. 821-826. [DOI: https://dx.doi.org/10.1002/pbc.24857]

18. Temming, P.; Arendt, M.; Viehmann, A.; Eisele, L.; Le Guin, C.H.D.; Schündeln, M.M.; Biewald, E.; Astrahantseff, K.; Wieland, R.; Bornfeld, N. et al. Incidence of second cancers after radiotherapy and systemic chemotherapy in heritable retinoblastoma survivors: A report from the German reference center. Pediatr. Blood Cancer; 2017; 64, pp. 71-80. [DOI: https://dx.doi.org/10.1002/pbc.26193]

19. Lewandowska, A.M.; Rudzki, M.; Rudzki, S.; Lewandowski, T.; Laskowska, B. Environmental risk factors for cancer—Review paper. Ann. Agric. Environ. Med.; 2019; 26, pp. 1-7. [DOI: https://dx.doi.org/10.26444/aaem/94299]

20. Thompson, S.; Ritz, B.; Cockburn, M.; Heck, J.E. Prenatal ambient pesticide exposure and childhood retinoblastoma. Int. J. Hyg. Environ. Health; 2022; 245, 114025. [DOI: https://dx.doi.org/10.1016/j.ijheh.2022.114025]

21. Heck, J.E.; Park, A.S.; Qiu, J.; Cockburn, M.; Ritz, B. Retinoblastoma and ambient exposure to air toxics in the perinatal period. J. Expo. Sci. Environ. Epidemiol.; 2015; 25, pp. 182-186. [DOI: https://dx.doi.org/10.1038/jes.2013.84] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24280682]

22. García-Pérez, J.; Morales-Piga, A.; Gómez-Barroso, D.; Tamayo-Uria, I.; Pardo Romaguera, E.; López-Abente, G.; Ramis, R. Residential proximity to environmental pollution sources and risk of rare tumors in children. Environ. Res.; 2016; 151, pp. 265-274. [DOI: https://dx.doi.org/10.1016/j.envres.2016.08.001]

23. Ferrís ITortajada, J.; Berbel Tornero, O.; Ortega García, J.A.; Claudio-Morales, L.; García ICastell, J.; Martí Perales, V.; Casas, L.M. Risk factors for pediatric malignant bone tumors. An. Pediatr.; 2005; 63, pp. 537-547. [DOI: https://dx.doi.org/10.1016/s1695-4033(05)70254-x]

24. Wong, J.R.; Morton, L.M.; Tucker, M.A.; Abramson, D.H.; Seddon, J.M.; Sampson, J.N.; Kleinerman, R.A. Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.; 2014; 32, pp. 3284-3290. [DOI: https://dx.doi.org/10.1200/JCO.2013.54.7844] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25185089]

25. Abramson, D.H.; Ronner, H.J.; Ellsworth, R.M. Second tumors in nonirradiated bilateral retinoblastoma. Am. J. Ophthalmol.; 1979; 87, pp. 624-627. [DOI: https://dx.doi.org/10.1016/0002-9394(79)90293-9]

26. Abramson, D.H.; Servodidio, C.A. Retinoblastoma. Optom. Clin.; 1993; 3, pp. 49-61.

27. Moll, A.C.; Imhof, S.M.; Bouter, L.M.; Kuik, D.J.; Den Otter, W.; Bezemer, P.D.; Koten, J.W.; Tan, K.E. Second primary tumors in patients with hereditary retinoblastoma: A register-based follow-up study, 1945–1994. Int. J. Cancer; 1996; 67, pp. 515-519. [DOI: https://dx.doi.org/10.1002/(SICI)1097-0215(19960807)67:4<515::AID-IJC9>3.0.CO;2-V]

28. Malumbres, M.; Carnero, A. Cell cycle deregulation: A common motif in cancer. Prog. Cell Cycle Res.; 2003; 5, pp. 5-18.

29. Kowalewski, A.A.; Randall, R.L.; Lessnick, S.L. Cell Cycle Deregulation in Ewing’s Sarcoma Pathogenesis. Sarcoma; 2011; 2011, 598704. [DOI: https://dx.doi.org/10.1155/2011/598704]

30. Hu, H.-M.; Zielinska-Kwiatkowska, A.; Munro, K.; Wilcox, J.; Wu, D.Y.; Yang, L.; Chansky, H.A. EWS/FLI1 suppresses retinoblastoma protein function and senescence in Ewing’s sarcoma cells. J. Orthop. Res. Off. Publ. Orthop. Res. Soc.; 2008; 26, pp. 886-893. [DOI: https://dx.doi.org/10.1002/jor.20597]

31. Kitchin, F.D.; Ellsworth, R.M. Pleiotropic effects of the gene for retinoblastoma. J. Med. Genet.; 1974; 11, pp. 244-246. [DOI: https://dx.doi.org/10.1136/jmg.11.3.244]

32. Schifter, S.; Vendelbo, L.; Jensen, O.M.; Kaae, S. Ewing’s tumor following bilateral retinoblastoma. A case report. Cancer; 1983; 51, pp. 1746-1749. [DOI: https://dx.doi.org/10.1002/1097-0142(19830501)51:9<1746::AID-CNCR2820510930>3.0.CO;2-G] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/6339032]

33. Helton, K.J.; Fletcher, B.D.; Kun, L.E.; Jenkins, J.J., III; Pratt, C.B. Bone tumors other than osteosarcoma after retinoblastoma. Cancer; 1993; 71, pp. 2847-2853. [DOI: https://dx.doi.org/10.1002/1097-0142(19930501)71:9<2847::AID-CNCR2820710928>3.0.CO;2-E] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/8467462]

34. Kay, R.M.; Eckardt, J.J.; Mirra, J.M. Osteosarcoma and Ewing’s Sarcoma in a Retinoblastoma Patient. Clin. Orthop. Relat. Res.; 1996; 323, pp. 284-287. [DOI: https://dx.doi.org/10.1097/00003086-199602000-00039] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/8625593]

35. Ceha, H.M.; Balm, A.J.; de Jong, D.; van ’t Veer, L.J. Multiple malignancies in a patient with bilateral retinoblastoma. J. Laryngol. Otol.; 1998; 112, pp. 189-192.

36. Mohney, B.G.; Robertson, D.M.; Schomberg, P.J.; Hodge, D.O. Second nonocular tumors in survivors of heritable retinoblastoma and prior radiation therapy. Am. J. Ophthalmol.; 1998; 126, pp. 269-277. [DOI: https://dx.doi.org/10.1016/S0002-9394(98)00146-9]

37. Aerts, I.; Pacquement, H.; Doz, F.; Mosseri, V.; Desjardins, L.; Sastre, X.; Michon, J.; Rodriguez, J.; Schlienger, P.; Zucker, J.-M. et al. Outcome of second malignancies after retinoblastoma: A retrospective analysis of 25 patients treated at the Institut Curie. Eur. J. Cancer; 2004; 40, pp. 1522-1529. [DOI: https://dx.doi.org/10.1016/j.ejca.2004.03.023]

38. Okeda, R.; Kanazawa, A.; Yamada, M.; Ohkawa, Y.; Kawabata, K.; Yoshida, M.A.; Ikeuchi, T. A 14-year-old patient with Ewing’s sarcoma presenting at autopsy with multiple neurofibrillary tangles and Lewy bodies in addition to hemiatrophy of the central nervous system. Clin. Neuropathol.; 1997; 16, pp. 77-84.

39. Mittal, R.; Al Awadi, S.; Sahar, O.; Behbehani, A.M. Ewing’s Sarcoma as Second Malignant Neoplasm after Retinoblastoma: A Case Report. Med. Princ. Pr.; 2008; 17, pp. 84-85. [DOI: https://dx.doi.org/10.1159/000109597]

40. Tahasildar, N.; Goni, V.; Bhagwat, K.; Tripathy, S.K.; Panda, B.B. Ewing’s sarcoma as second malignancy following a short latency in unilateral retinoblastoma. J. Orthop. Traumatol.; 2011; 12, pp. 167-171. [DOI: https://dx.doi.org/10.1007/s10195-011-0152-0]